Search Input
Log in
Sign up
Watch fullscreen
Regeneron Delivers Strong Third Quarter But Sees Higher R&D
The Street
Follow
Like
Favorite
Share
Add to Playlist
Report
4 years ago
Regeneron posts earnings that beat forecasts but cautions ongoing development of its Covid-19 vaccine candidate and other drugs mean higher R&D costs.
Show less
Recommended
0:35
I
Up next
[Read] Patents for Chemicals, Pharmaceuticals and Biotechnology For Kindle
Asher Battle
0:39
[Read] Patents for Chemicals, Pharmaceuticals and Biotechnology Best Sellers Rank : #2
dm_c323e93634b6d3108b10f21040648af2
9:59
THE RUNDOWN | Teva Pharmaceuticals reports jump in earnings | Thursday, May 3rd 2018
i24NEWS (English)
0:40
Popular Patents for Chemicals, Pharmaceuticals, and Biotechnology
kilivi